Welcome!

Microsoft Cloud Authors: John Basso, Liz McMillan, Pat Romanski, Glenn Rossman, Elizabeth White

News Feed Item

Synthesis Polypeptide Drug Market (Global and China) Research Report for 2012

DALLAS, November 30, 2012 /PRNewswire/ --

RnRMarketResearch.com adds new market research report "2012 Deep Research Report on Global and China Synthesis Polypeptide Drug Industry" to its store.

2012 Deep Research Report on Global and China Synthesis Polypeptide Drug Industry is a professional and in-depth research report on China Synthesis Polypeptide Drug market. The report introduces Synthesis Polypeptide Drug with basic information including definition, classification, application, industry chain structure, industry overview and more. The research covers international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis and influence, Synthesis Polypeptide Drug industry policy and plan, Synthesis Polypeptide Drug product specification, manufacturing process, product cost structure, etc. Statistics of China's key manufacturers of Synthesis Polypeptide Drug with their capacity production cost price profit production value gross margin and other details are also covered. In addition to the above said information, the study also presents products and their customers, application, capacity, market position, company contact information and other related information of these companies. The report also covers all these manufacturers' data and lists China Synthesis Polypeptide Drug capacity production capacity market share production market share supply demand shortage import export consumption etc data statistics, and then introduced China Synthesis Polypeptide Drug 2009-2013 capacity production price cost profit production value gross margin etc information. And also lists Synthesis Polypeptide Drug upstream raw materials equipments and Sharp Solarnstream clients alternative products survey analysis and Synthesis Polypeptide Drug marketing channels industry development trend and proposals. In the end, this report introduced Synthesis Polypeptide Drug new project SWOT analysis Investment feasibility analysis investment return analysis and also give related research conclusions and development trend analysis of China Synthesis Polypeptide Drug industry. In a word, it was a depth research report on China Synthesis Polypeptide Drug industry. And thanks to the support and assistance from Synthesis Polypeptide Drug industry chain related technical experts and marketing engineers during Research Team survey and interviews.

Buy your copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=57872

Table of Contents for the report "2012 Deep Research Report on Global and China Synthesis Polypeptide Drug Industry" cover:

Chapter One Synthesis Polypeptide Drug Industry Overview    1
1.1 Synthesis Polypeptide Drug Definition    1
1.2 Synthesis Polypeptide Drug Classification and Application    3
1.3 Professional Terms Interpretation    8
1.4 Synthesis Polypeptide Drug Industry Chain Structure    12
1.5 Synthesis Polypeptide Drug Industry Overview    14
Chapter Two Synthesis Polypeptide Drug International and China Market Analysis    16
2.1 Synthesis Polypeptide Drug Industry International Market Analysis    16
2.1.1 Synthesis Polypeptide Drug International Market Development History    16
2.1.2 Synthesis Polypeptide Drug Product and Technology Developments    18
2.1.3 Synthesis Polypeptide Drug Competitive Landscape Analysis    25
2.1.4 Synthesis Polypeptide Drug International Key Countries Development Status    28
2.1.5 Synthesis Polypeptide Drug International Market Development Trend    30
2.2 Synthesis Polypeptide Drug China Market Analysis    33
2.2.1 Synthesis Polypeptide Drug China Market Development History    33
2.2.2 Synthesis Polypeptide Drug Product and Technology Developments    33
2.2.3 Synthesis Polypeptide Drug Competitive Landscape Analysis    35
2.2.4 Synthesis Polypeptide Drug China Key Regions Development Status    37
2.2.5 Synthesis Polypeptide Drug China Market Development Trend    37
2.3 Synthesis Polypeptide Drug International and China Market Comparison Analysis    42
Chapter Three Major Synthesis Polypeptide Drug Analysis    43
3.1 Immunity Regulating Medicine (Allergy Infection and Immune)    43
3.1.1 Glatiramer Injection (Glatiramer Acetate)    43
3.1.2 Thymalfasin for Injection    46
3.1.3 Thymopentin Injection    49
3.1.4 Thymopetidum Injection    53
3.1.5 Summary    55
3.2 Digestive System Drugs (Gastrointestinal Type)    57
3.2.1 Octreotide Acetate Injection    57
3.2.2 Somatostatin for Injection    61
3.3 Bone and Connective Tissue Types (Thyroid hormones Drug)    66
3.3.1 Salmon Calcitonin Injection    67
3.3.2 Elcatonin Injection    70
3.3.4 TerfparaLide Injectlon    72
3.4 Gynecologic or Obstetric Drug    76
3.4.1 Oxytocin Injection    76
3.4.2 Carbetocin Injection    81
3.4.3 Acetate Atosiban Injection    83
3.5 Tumor Drug (hCG)    86
3.5.1 Leuprorelin Acetate Microspheres for Injection    87
3.5.2 Goserelin Acetate    89
3.5.3 Triptorelin Acetate Injection    92
3.5.4 Chorionic Gonadotrophin for Injection    95
3.6 Urinary System Drug (Diabetes Insipidus)    98
3.6.1 Desmopressin Acetate Injection    98
3.6.2 Terlipressin for Injection    101
3.7 Metabolic Drug (Insulin and Other Hypoglycemic Agents)    105
3.7.1 Biosynthetic Glucagon for Injection    105
3.7.2 Exenatide Injection    106
Chapter Four Synthesis Polypeptide Drug Development Environmental Analysis    109
4.1 China's Macroeconomic Environment Analysis    109
4.1.1 China GDP Analysis    109
4.1.2 China CPI Analysis    111
4.2 European Economic Environmental Analysis and Impact    113
4.3 United States Economic Environmental Analysis and Impact    116
4.4 Japan Economic Environmental Analysis and Impact    119
4.5 Global Economic Environmental Analysis and Impact    120
4.5.1 Global Economic Environmental Analysis    120
4.5.2 Global Economic Influence    121
Chapter Five Synthesis Polypeptide Drug Development Policy and Plan    121
5.1 China Government Policy and Development Plan    121
5.2 Industry Policy and Standard    122
5.3 Technical Standard    125
5.4 Technology Replacement and R&D Trends    126
5.5 Hotspots and Influence    127
Chapter Six Synthesis Polypeptide Drug Manufacturing Process and Cost Structure    132
6.1 Synthesis Polypeptide Drug Manufacturing Process Overview    132
6.2 Synthesis Polypeptide Drug Manufacturing Process Analysis    135
6.3 Synthesis Polypeptide Drug Cost Structure Analysis    138
Chapter Seven 2009-2013 Synthesis Polypeptide Drug Productions Supply Sales Demand Market Status and Forecast    140
7.1 2009-2013 Synthesis Polypeptide Drug Capacity Production Overview    140
7.1.1 2009-2013 Global and China Synthesis Polypeptide Drug Capacity Production    140
7.1.2 2009-2013 Synthesis Polypeptide Drug Production Market Share    146
7.1.3 2009-2013 Synthesis Polypeptide Drug Demand Overview    152
7.1.4 2009-2013 Synthesis Polypeptide Drug Supply Demand and Shortage    152
7.1.5 2009-2013 Synthesis Polypeptide Drug Production Import Export Consumption    153
7.1.6 2009-2013 Synthesis Polypeptide Drug Cost Price Production Value Gross Margin    154
7.2 Different Type Synthesis Polypeptide Drug Sales and Market Scale Analysis    156
7.2.1Thymopentin Injection    156
7.2.2 Thymalfasin Injection    158
7.2.3 Calcitonin Injection    159
7.2.4 Somatostatin for Injection    161
7.2.5Octreotide Acetate Injection    162
7.2.6 Desmopressin Acetate Injection    163
7.3 Synthesis Polypeptide Drug Market Summary    165
Chapter Eight Synthesis Polypeptide Drug Key Manufacturers (Company Profiles)   170
8.1 Novartis    170
8.2 Merck Serono    176
8.3 Ferring Pharmaceuticals    181
8.4 Ipsen PHarma Biotech    188
8.5 Lilly    191
8.6 Asahi Kasei    195
8.7 AstraZeneca    199
8.8 SciClone Pharmaceuticals    203
8.9 Takeda    206
8.10 HYBIO Pharmaceutical Co.,Ltd (Shenzhen Stock:300199)    210
8.11 Hainan Zhonghe Pharmaceutical Co.,Ltd    215
8.12 Sichuan Chengdu Diao Pharmaceutical Group Co.,Ltd    219
8.13 Beijing Yingu Century Pharmaceutical Co.,Ltd (Beijing Shiqiao Bio-Pharmaceutical Co.,Ltd)    224
8.14 Hainan Shuangcheng Pharmaceuticals Co.,Ltd    227
8.15 Livzon Pharmaceuticals Co.,Ltd (Livzon:000513)    234
8.16 Wuhan Hualong Bio-Chemical Pharmaceutical Co.,Ltd    238
8.17 Chengdu Tiantaishan Pharmaceutical Co.,Ltd    242
8.18 Beijing Shuanglu Pharmaceutical Co.,Ltd    250
8.19 Yangzijiang Pharmaceutical Co.,Ltd    257
8.20 Changzhou Siyao Pharmaceutical Co.,Ltd    262
Chapter Nine Up and Down Stream Industry Analysis and Influence    267
9.1 Upstream Raw Materials Price Analysis and Influence    267
9.1 Upstream Equipments Market Analysis and Influence    269
9.3 Downstream Demand Analysis and Influence    270
9.4 Industry Policy Analysis and Influence    271
Chapter Ten Synthesis Polypeptide Drug Marketing Channels Analysis    272
10.1 Synthesis Polypeptide Drug Marketing Channels Status    272
10.1.1 Drugs Marketing Channel Developemnt History    272
10.1.1 Prescription Drug Marketing Development Status    273
10.2 Synthesis Polypeptide Drug Marketing Channels Management    274
10.3 Synthesis Polypeptide Drug Marketing Channels Establishment    275
10.4 Synthesis Polypeptide Drug Marketing Channels Development Trend    276
Chapter Eleven Synthesis Polypeptide Drug Industry Development Trend    278
11.1 2012-2016 Synthesis Polypeptide Drug Industry Development Trend    278
11.2 2012-2016 Market Potential Forecast    279
11.3 2012-2016 R&D Trend    280
11.3.1Polypeptide Drug Technical Development Status    280
11.3.2 Polypeptide Drug and Health Care Products Research and Manufacturing Overview    282
11.3.3 China Polypeptide Drug Development Direction and Prospect    283
11.4 2012-2016 Marketing Channels Change Trend    285
14.4.1 Prescription Drug Marketing Channels Change Trend    285
14.4.2 Prescription Drug Sales Method Five Trend    286
11.5 2012-2016 Competition Pattern Development Trends    288
Chapter Twelve Synthesis Polypeptide Drug Industry Development Proposals    289
12.1 Macroeconomic Development Countermeasures    289
12.2 New Firms Enter Market Strategy    290
12.2.1 New Business Entry Barriers    290
12.2.2 New Corporate Strategy    290
12.3 New Project Investment Proposal    293
12.4 Marketing Channel Strategy Proposals    294
12.5 Competitive Environment Strategy Proposals    296
12.5.1 Competitive Environment Analysis    296
12.5.2 Strategy Proposals    297
Chapter Thirteen Synthesis Polypeptide Drug New Project Investment Feasibility Analysis    300
13.1 Synthesis Polypeptide Drug Project SWOT Analysis    300
13.2 Synthesis Polypeptide Drug New Project Investment Feasibility Analysis    302
13.2.1 Buildings    302
13.2.2 Investment    303
13.2.3 Project Schedule    303
13.2.4 Project Investment Return and Feasibility Analysis    304
Chapter Fourteen Synthesis Polypeptide Drug Industry Research Conclusions    304

 

List Of Tables and Figures

Figure Synthesis Polypeptide Process Flow    1
Figure Synthesis Polypeptide Drug Picture-Thymopentin Injection    2
Figure Polypeptide Applications on Health Care Food and Cosmetics Fields    4
Figure Polypeptide Drug Manufacturing Process Method    4
Table Synthesis Polypeptide Drug Classification and Application List    5
Table Synthesis Polypeptide Drug Product Name Use and Annual Sales Revenue (USD) List    6
Table Listed Polypeptide Drug Name Type Indication    6
Figure Pharmaceutical Industry Value Chain Structure    12
Figure Pharmaceutical Industry Industry Chain Structure    12
Figure Synthesis Polypeptide Drug Industry Chain Structure    13
Figure Synthesis Polypeptide Drug Industrialization System    13
Figure 2000-2011 China Pharmaceutical Industry Sales Revenue and Total Profit (100 Million RMB) and Growth Rate    14
Figure 2007-2015 China Synthesis Polypeptide Drug Market Scale (100 Million RMB) and Growth Rate    15
Figure DNA Transcribed into RNA Diagram    17
Figure RNA Translated into Polypeptide Chains Molecular Diagram    18
Table Polypeptide Drug Three Manufacturing Methods    19
Figure 1984 Chemistry Nobel Prize Winner Robert Bruce Merrifield    20
Figure Polypeptide Solid Phase Synthesis Principle    20
Figure Solid Phase Polypeptide Synthesis    21
Figure United States CS Three Channel Full Automatic Polypeptide Synthetic Instrument    22
Figure Homemade CS136 Model Research Polypeptide Synthetic Instrument    23
Figure Large Scale Liquid Phase Synthesis of Polypeptide    24
Figure Thin Film Evaporator (for perishable goods Concentration)    24
Table Global 2008 Revenue More than 1 Billion Polypeptide Drug Brands List    25
Table Some Listed Polypeptide Drug Indication Classification    26
Figure Listed Polypeptide Drug Indication Classification Market Share    26
Figure 2004-2014 Global Pharmaceutical Sales Revenue (Billion USD) and Growth Rate    30
Figure 2009-2013 International Synthesis Polypeptide Drug Market Scale (100 Million RMB) and Growth Rate    31
Table 2011 Some Polypeptide Drug Global Sales Revenue (100 Million USD)    31
Figure Each Year Enter Clinical Research Polypeptide Drug Quantity (Piece)    32
Table 17 Emerging Pharmaceutical Market Sizes (Billion USD)    38
Figure 2007-2015 China Pharmaceutical Sales Revenue (100 Million USD)    39
Figure 2009-2015 China Polypeptide Drug Market Scale (100 Million RMB) and Growth Rate    39
Figure 2009-2015 China Chemical Synthesis Polypeptide Drug Market Scale (100 Million RMB) and Growth Rate    40
Figure 2009-2015 China Chemical Synthesis Polypeptide Drug Market Scale (100 Million RMB) and Proportion of China Total Polypeptide Drug Market Scale    41
Figure 2007-2009 China Chemical Synthesis Polypeptide Drug Types Market Share    41
Table Copaxone Neuron Structure Diagram    44
Table Thymalfasin for Injection (Thymalfasin a1) Suppliers List    48
Table 2010 Thymalfasin for Injection Key Products Price (RMB/Piece) List    49
Table Some Thymopentin Injection Suppliers List    51
Table Thymopentin Injection Hospital Purchase Price (RMB/Piece) List    52
Table Thymopetidum Injection Thymopentin Injection Thymalfasin Injection Comparison    56
Table Octreotide Acetate Injection Key Suppliers List    59
Table 2012 Hebei Province Octreotide Acetate Injection Bid Price List    60
Tale Somatostatin for Injection Key Suppliers List    64
Table Somatostatin for Injection Key Products Hospital Average Purchae Price List    64
Table 2012 Hebei Province Somatostatin for Injection Key Suppliers List    65
Table Salmon Calcitonin Injection Suppliers List    69
Table Salmon Calcitonin Injection/Nasal Spray Products Hospital Purchase Price List    69
Table Salmon Calcitonin Injection/Nasal spray Products Retail Price List    70
Table Elcatonin Injection Key Suppliers and Product Selling Price List    72
Figure TerfparaLide Injectlon-Forsteo Injection Pen Parts    75
Table 2011Q1 China Some Aproved New Drug Number, Specifications Suppliers and Indication    76
Table 2012 New Add Key Monitoring Drug Table--TerfparaLide Injectlon    76
Table Oxytocin Injection Key Suppliers List    78
Table Oxytocin Injection Suppliers Products Models List    80
Table Carbetocin Injection Suppliers List    83
Table Acetate Atosiban Injection Supplier Product Specification Price List    85
Table Leuprorelin Acetate Microspheres for Injection Suppliers Product Specification Price List    88
Table Triptorelin Acetate Injection Suppliers Product Specification Price List    94
Table Chorionic Gonadotrophin for Injection Suppliers Product Specifications List    97
Table 2011 Some Hormone Drugs Independent Pricing and Uniform Pricing Comparison    98
Table Desmopressin Acetate Injection Key Suppliers List    100
Table Desmopressin Acetate Injection Key Suppliers Forms Product Specifications and Bid Price List    101
Table Terlipressin for Injection Key Brands Manufacturers and Retail Prices    104
Table Biosynthetic Glucagon for Injection Suppliers and Retail Prices List    106
Table Exenatide Suppliers Product Specifications Retail Prices List    109
Figure 2007-2015 China Medical Industry Total Production Value (100 Million RMB) and Growth Rate    110
Table 2006-2011 China GDP (1000 Million RMB) and Growth Rate    110
Figure 2007-2011 China Medical Industry Total Value and Its Proportion of China Total GDP    111
Figure 2007-2015 China Individual Medical Expenditure (RMB)    112
Figure 2007-2015 China Health Expenditure Per Capita and National Medical Expenditure Comparison    112
Figure 2011-2016 China Population Growth and Aging Condition    113
Figure 2006-2011 Europe Several Countries PMI Trend    114
Figure United States CPI and PCE Growth Comparison    117
Figure United States Private Savings Rate Change and Net Export /GDP Proportion Change Trend    118
Figure United States Public Debt and Deficit Proportion of GDP    119
Figure Japan GDP and CPI Growth Rate Comparison    119
Figure 2009-2011 China Health Capital Investment (100 Million RMB)    122
Table China Pharmaceutical Industry All major Departments and Regulatory Functions    122
Table Pharmaceutical Industry main Laws and Regulations and Policies    125
Table 2009-2012 China Medical and Health System Reform Important Policy    128
Table 2009-2012 China Related Pharmaceutical Product Quality Supervision Policy    129
Table 2008-2012 China Development and Reform Commission Policy on Drug Price Management Policies    130
Figure PTIPolypeptide Synthetic Instruments Picture    133
Table Synthesis Polypeptide Drug Technology Processes List    133
Figure Polypeptide Pharmaceutical Raw Materials Manufacturing Process Flow    135
Figure Freeze Dried Powder Injection Manufacturing Process Flow    136
Figure Small Capacity Injection Manufacturing Process Flow    136
Figure Thymalfasin API Manufacturing Process Flow    137
Figure Thymalfasin Injection Manufacturing Process Flow    138
Figure International Synthesis Polypeptide Drug Cost Structure    139
Table 2009-2011 China Synthesis Polypeptide Drug Cost Structure    139
Table 2009-2013 Global Key Manufacturers Synthesis Polypeptide Drug Capacity and Total Capacity (10K Piece) List    140
Table 2009-2013 Global Key Manufacturers Synthesis Polypeptide Drug Capacity Market Share List    140
Table 2009-2013 Global Key Manufacturers Synthesis Polypeptide Drug Production and Total Production (10K Piece) List    141
Table 2009-2013 Global Key Manufacturers Synthesis Polypeptide Drug Production Market Share List    141
Table 2009-2013 China Key Manufacturers Synthesis Polypeptide Drug Capacity and Total Capacity (10K Piece) List    142
Table 2009-2013 China Key Manufacturers Synthesis Polypeptide Drug Capacity Market Share List    142
Table 2009-2013 China Key Manufacturers Synthesis Polypeptide Drug Production and Total Production (10K Piece) List    143
Table 2009-2013 China Key Manufacturers Synthesis Polypeptide Drug Production Market Share List    143
Figure 2009-2013 Global Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    144
Table 2009-2013 Global Synthesis Polypeptide Drug Capacity Utilization Rate List    144
Figure 2009-2013 China Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    145
Table 2009-2013 China Synthesis Polypeptide Drug Capacity Utilization Rate List    145
Table 2009-2013 Key Manufacturers Synthesis Polypeptide Drug China Sales (10K Piece) Top20 List    146
Table 2009-2013 Key Manufacturers Synthesis Polypeptide Drug China Sales Top20 Market Share List    147
Table 2010 Key Manufacturers Synthesis Polypeptide Drug China Sales Revenue (100 Million RMB) Top10 List    147
Table 2008-2010 Key Manufacturers Synthesis Polypeptide Drug China Sales Revenue Top10 Market Share List    148
Figure 2011 Key Manufacturers Synthesis Polypeptide Drug China Sales Market Share    149
Figure 2012 Key Manufacturers Synthesis Polypeptide Drug China Sales TOP20 Market Share    150
Figure 2011 China Key Manufacturers Synthesis Polypeptide Drug Production Market Share    151
Figure 2012 China Key Manufacturers Synthesis Polypeptide Drug Production Market Share    151
Table 2009-2013 Global Synthesis Polypeptide Drug Demand (10K Piece) and Growth Rate    152
Table 2009-2013 China Synthesis Polypeptide Drug Demand (10K Piece) and Growth Rate    152
Table 2009-2013 China Synthesis Polypeptide Drug Supply Demand and Shortage (10K Piece)    153
Table 2009-2013 Nine Foreign Enterprises Synthesis Polypeptide Drug China Sales (10K Piece) List    153
Table 2009-2013 China Synthesis Polypeptide Drug Production Import Export Consumption (10K Piece) List    154
Table 2007-2009 China Synthesis Polypeptide Drug Price (RMB/Piece) Distribution    154
Table 2009-2011 Hainan Shuangcheng Pharmaceuticals Some Synthesis Polypeptide Drug Price Cost (RMB/Piece) Gross Margin List    155
Table 2009-2013 China Synthesis Polypeptide DrugProduction (10K Piece) Price Cost Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    155
Figure 2011 China Synthesis Polypeptide Drug Market Share by Different Type Drug    156
Figure 2008-2014 China Thymopentin Injection Market Scale (100 Million RMB) and Growth Rate    157
Figure 2008-2014 China Thymopentin Injection Sales (10K Piece) and Growth Rate    157
Figure 2008-2014 China Thymalfasin Injection Market Scale (100 Million RMB) and Growth Rate    158
Figure 2008-2014 China Thymalfasin Injection Sales (10K Piece) and Growth Rate    159
Figure 2008-2014 China Calcitonin Injection Market Scale (100 Million RMB) and Growth Rate    160
Figure 2008-2014 China Calcitonin Injection Sales (10K Piece) and Growth Rate    160
Figure 2008-2014 China Somatostatin for Injection Market Scale (100 Million RMB) and Growth Rate    161
Figure 2008-2014 China Somatostatin for Injection Sales (10K Piece) and Growth Rate    162
Figure 2008-2014 China Octreotide Acetate Injection Market Scale (100 Million RMB) and Growth Rate    163
Figure 2008-2014 China Octreotide Acetate Injection Sales (10K Piece) and Growth Rate    163
Figure 2008-2014 China Desmopressin Acetate Injection Market Scale (100 Million RMB) and Growth Rate    164
Figure 2008-2014 China Desmopressin Acetate Injection Sales (10K Piece) and Growth Rate    164
Table 2009-2011 China Chemical Synthesis Polypeptide Drug Injection Distribution List    165
Figure 2010 Global Polypeptide Drug Market Structure by Treatment Class    165
Table Research or Listed Polypeptide Drugs List    166
Figure 1990-2010 China Resident Three Types of Chronic Disease Prevalence (1/100K) Change Trend    167
Figure 2010 China Synthesis Polypeptide Drug Hospital Terminal Sales Market Share Distribution    168
Figure 2010 China Synthesis Polypeptide Drug Top10 Manufacturers Sales Revenue (100 Million RMB)    168
Figure China Synthesis Polypeptide Drug Prices Distribution    169
Figure Use Me-Too Model Developed Polypeptide Drug List    169
Table Novartis Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    170
Figure Novartis China Market Sales Synthesis Polypeptide Drug--Octreotide Acetate Injection    173
Figure Novartis China Market Sales Synthesis Polypeptide Drug--Somatostatin Acetate for Injection    173
Figure Novartis China Market Sales Synthesis Polypeptide Drug--salmon Calcitonin Nasal Spray    174
Table 2009-2013 Novartis Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    174
Figure 2009-2013 Novartis Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    175
Table Merck Serono Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    176
Figure Merck Serono Synthesis Polypeptide Drug--Recombinant Human Follitropin Alfa Solution for Injection    178
Figure Merck Serono Synthesis Polypeptide Drug--Somatostatin for Injection    179
Figure Merck Serono Synthesis Polypeptide Drug--Gonadorelin for Injection    179
Table 2009-2013 Merck Serono Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    180
Figure 2009-2013 Merck Serono Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    181
Table Ferring Pharmaceuticals Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    182
Figure Ferring Pharmaceuticals China Market Sales Synthesis Polypeptide Drug--Minirin    183
Figure Ferring Pharmaceuticals China Market Sales Synthesis Polypeptide Drug--Decapeptyl    184
Figure Ferring Pharmaceuticals China Market Sales Synthesis Polypeptide Drug--Pentasa    184
Figure Ferring Pharmaceuticals China Market Sales Synthesis Polypeptide Drug--Glypressin    185
Figure Ferring Pharmaceuticals China Market Sales Synthesis Polypeptide Drug--Octostim    186
Table 2009-2013 Ferring Pharmaceuticals Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    186
Figure 2009-2013 Ferring Pharmaceuticals Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    188
Table Ipsen PHarma Biotech Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    188
Figure Ipsen PHarma Biotech  Synthesis Polypeptide Drug--Triptorelin Acetate for Injection    190
Table 2009-2013 Ipsen PHarma Biotech Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    190
Figure 2009-2013 Ipsen PHarma Biotech Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    191
Table Lilly Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    192
Figure Lilly Some China Listed Synthesis Polypeptide Drug List    194
Table 2009-2013 Lilly Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    194
Figure 2009-2013 Lilly Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    195
Table Asahi Kasei Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    195
Figure Asahi Kasei Synthesis Polypeptide Drug--Elcatonin Injection    198
Table 2009-2013 Asahi Kasei Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    198
Figure 2009-2013 Asahi Kasei Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    199
Table AstraZeneca Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    199
Figure AstraZeneca China Selling Synthesis Polypeptide Drug-Goserelin Acetate Slow Release Implantation Agent    201
Table 2009-2013 Jiangsu AstraZeneca Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    202
Figure 2009-2013 Jiangsu AstraZeneca Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    203
Table SciClone Pharmaceuticals Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    204
Figure SciClone Pharmaceuticals Synthesis Polypeptide Drug-- Thymopetidum α1 Injection    205
Table 2009-2013 SciClone Pharmaceuticals Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    205
Figure 2009-2013 SciClone Pharmaceuticals Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    206
Table Takeda Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    206
Figure Takeda--Leuprorelin Acetate Microspheres for Injection    208
Table 2009-2013 Takeda Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    209
Figure 2009-2013 Takeda Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    209
Table HYBIO Pharmaceutical Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    210
Figure 2009-2013 HYBIO Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug    211
Table 2009-2013 HYBIO Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    213
Figure 2009-2013 HYBIO Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    215
Table Hainan Zhonghe Pharmaceutical Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    216
Figure Hainan Zhonghe Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug产品    217
Table 2009-2013 Hainan Zhonghe Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    217
Figure 2009-2013 Hainan Zhonghe Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    219
Table Sichuan Chengdu Diao Pharmaceutical Group Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    219
Figure Sichuan Chengdu Diao Pharmaceutical Group Co.,Ltd Synthesis Polypeptide Drug-Thymalfasin Injection    221
Figure Sichuan Chengdu Diao Pharmaceutical Group Co.,Ltd Synthesis Polypeptide Drug-Thymopentin Injection    222
Table 2009-2013 Sichuan Chengdu Diao Pharmaceutical Group Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    222
Figure 2009-2013 Sichuan Chengdu Diao Pharmaceutical Group Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    223
Table Beijing Yingu Century Pharmaceutical Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    224
Figure Beijing Yingu Century Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Salmon Calcitonin Nasal Spray    225
Figure Beijing Yingu Century Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Thymopentin Injection    226
Table 2009-2013 Beijing Yingu Century Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    226
Figure 2009-2013 Beijing Yingu Century Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    227
Table Hainan Shuangcheng Pharmaceuticals Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    228
Figure Hainan Shuangcheng Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug--Thymalfasin Injection(基泰)    229
Figure Hainan Shuangcheng Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug-Somatostatin for Injection    231
Figure Hainan Shuangcheng Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug-Thymopentin Injection (双成可维)    232
Table 2009-2013 Hainan Shuangcheng Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    233
Figure 2009-2013 Hainan Shuangcheng Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    234
Table Livzon Pharmaceuticals Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    234
Figure Livzon Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug    236
Table 2009-2013 Livzon Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    236
Figure 2009-2013 Livzon Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    238
Table Wuhan Hualong Bio-Chemical Pharmaceutical Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    239
Figure Wuhan Hualong Bio-Chemical Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug--Thymopentin Injection    240
Figure Wuhan Hualong Bio-Chemical Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug--Somatostatin for Injection    240
Table 2009-2013 Wuhan Hualong Bio-Chemical Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    241
Figure 2009-2013 Wuhan Hualong Bio-Chemical Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    242
Table Chengdu Tiantaishan Pharmaceutical Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    242
Figure Chengdu Tiantaishan Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Somatostatin for Injection    244
Figure Chengdu Tiantaishan Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Thymopentin Injection    246
Figure Chengdu Tiantaishan Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Octreotide Acetate Injection    247
Table 2009-2013 Chengdu Tiantaishan Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    248
Figure 2009-2013 Chengdu Tiantaishan Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    249
Table Beijing Shuanglu Pharmaceutical Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    250
Figure Beijing Shuanglu Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Thymopentin Injection    251
Figure Beijing Shuanglu Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Salmon Calcitonin Injection    252
Table Beijing Shuanglu Pharmaceutical Co.,Ltd Thymopentin Injection Price List    253
Table 2009-2013 Beijing Shuanglu Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    256
Figure 2009-2013 Beijing Shuanglu Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    257
Table Yangzijiang Pharmaceutical Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    257
Figure Yangzijiang Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Somatostatin for Injection    259
Figure Yangzijiang Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Thymopentin Injection    260
Table 2009-2013 Yangzijiang Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    260
Figure 2009-2013 Yangzijiang Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    261
Table Changzhou Siyao Pharmaceutical Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    262
Figure Changzhou Siyao Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug List    264
Table Changzhou Siyao Pharmaceutical Co.,Ltd Chemical Pharmaceutical Raw Materials List    264
Table Changzhou Siyao Pharmaceutical Co.,Ltd Chemical Raw Materials Intermediates List    265
Table 2009-2013 Changzhou Siyao Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    266
Figure 2009-2013 Changzhou Siyao Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    266
Table Synthesis Polypeptide Drug Project Key Equipments and Price (10K RMB)    269
Table Synthesis Polypeptide Drug Project Equipments List and Price (10K RMB)    270
Table Drugs Manufacturing Enterprise Specialized Academic Promotion Organization Frame    276
Figure Synthesis Polypeptide Drug Industry Entry Barriers List    293
Table 2012 China Synthesis Polypeptide Drug New Project SWOT Analysis    300
Table 2012 China Synthesis Polypeptide Drug New Project Buildings List    302
Table 2012 China Synthesis Polypeptide Drug New Project Investments (10K RMB) List    303
Table Synthesis Polypeptide Drug New Project Investment Return and Feasibility Analysis    304

Browse more reports on the Pharmaceuticals Market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals.

Explore newly published market research reports on other industries and for different geographies @ http://www.rnrmarketresearch.com/latest_reports.

About Us:

RnRMarketResearch.com (http://www.rnrmarketresearch.com/) is an online market research reports library of 175,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

Contact:
Priyank Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
[email protected]
Explore more Industry reports @ http://www.marketreportsonline.com/.


SOURCE RnRMarketResearch

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
WebRTC is bringing significant change to the communications landscape that will bridge the worlds of web and telephony, making the Internet the new standard for communications. Cloud9 took the road less traveled and used WebRTC to create a downloadable enterprise-grade communications platform that is changing the communication dynamic in the financial sector. In his session at @ThingsExpo, Leo Papadopoulos, CTO of Cloud9, discussed the importance of WebRTC and how it enables companies to focus...
Verizon Communications Inc. (NYSE, Nasdaq: VZ) and Yahoo! Inc. (Nasdaq: YHOO) have entered into a definitive agreement under which Verizon will acquire Yahoo's operating business for approximately $4.83 billion in cash, subject to customary closing adjustments. Yahoo informs, connects and entertains a global audience of more than 1 billion monthly active users** -- including 600 million monthly active mobile users*** through its search, communications and digital content products. Yahoo also co...
A critical component of any IoT project is what to do with all the data being generated. This data needs to be captured, processed, structured, and stored in a way to facilitate different kinds of queries. Traditional data warehouse and analytical systems are mature technologies that can be used to handle certain kinds of queries, but they are not always well suited to many problems, particularly when there is a need for real-time insights.
Amazon has gradually rolled out parts of its IoT offerings in the last year, but these are just the tip of the iceberg. In addition to optimizing their back-end AWS offerings, Amazon is laying the ground work to be a major force in IoT – especially in the connected home and office. Amazon is extending its reach by building on its dominant Cloud IoT platform, its Dash Button strategy, recently announced Replenishment Services, the Echo/Alexa voice recognition control platform, the 6-7 strategic...
The best-practices for building IoT applications with Go Code that attendees can use to build their own IoT applications. In his session at @ThingsExpo, Indraneel Mitra, Senior Solutions Architect & Technology Evangelist at Cognizant, provided valuable information and resources for both novice and experienced developers on how to get started with IoT and Golang in a day. He also provided information on how to use Intel Arduino Kit, Go Robotics API and AWS IoT stack to build an application tha...
IoT generates lots of temporal data. But how do you unlock its value? You need to discover patterns that are repeatable in vast quantities of data, understand their meaning, and implement scalable monitoring across multiple data streams in order to monetize the discoveries and insights. Motif discovery and deep learning platforms are emerging to visualize sensor data, to search for patterns and to build application that can monitor real time streams efficiently. In his session at @ThingsExpo, ...
SYS-CON Events announced today that LeaseWeb USA, a cloud Infrastructure-as-a-Service (IaaS) provider, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. LeaseWeb is one of the world's largest hosting brands. The company helps customers define, develop and deploy IT infrastructure tailored to their exact business needs, by combining various kinds cloud solutions.
SYS-CON Events announced today that 910Telecom will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Housed in the classic Denver Gas & Electric Building, 910 15th St., 910Telecom is a carrier-neutral telecom hotel located in the heart of Denver. Adjacent to CenturyLink, AT&T, and Denver Main, 910Telecom offers connectivity to all major carriers, Internet service providers, Internet backbones and ...
Big Data, cloud, analytics, contextual information, wearable tech, sensors, mobility, and WebRTC: together, these advances have created a perfect storm of technologies that are disrupting and transforming classic communications models and ecosystems. In his session at @ThingsExpo, Erik Perotti, Senior Manager of New Ventures on Plantronics’ Innovation team, provided an overview of this technological shift, including associated business and consumer communications impacts, and opportunities it ...
SYS-CON Events announced today that Venafi, the Immune System for the Internet™ and the leading provider of Next Generation Trust Protection, will exhibit at @DevOpsSummit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Venafi is the Immune System for the Internet™ that protects the foundation of all cybersecurity – cryptographic keys and digital certificates – so they can’t be misused by bad guys in attacks...
It’s 2016: buildings are smart, connected and the IoT is fundamentally altering how control and operating systems work and speak to each other. Platforms across the enterprise are networked via inexpensive sensors to collect massive amounts of data for analytics, information management, and insights that can be used to continuously improve operations. In his session at @ThingsExpo, Brian Chemel, Co-Founder and CTO of Digital Lumens, will explore: The benefits sensor-networked systems bring to ...
Manufacturers are embracing the Industrial Internet the same way consumers are leveraging Fitbits – to improve overall health and wellness. Both can provide consistent measurement, visibility, and suggest performance improvements customized to help reach goals. Fitbit users can view real-time data and make adjustments to increase their activity. In his session at @ThingsExpo, Mark Bernardo Professional Services Leader, Americas, at GE Digital, discussed how leveraging the Industrial Internet a...
There will be new vendors providing applications, middleware, and connected devices to support the thriving IoT ecosystem. This essentially means that electronic device manufacturers will also be in the software business. Many will be new to building embedded software or robust software. This creates an increased importance on software quality, particularly within the Industrial Internet of Things where business-critical applications are becoming dependent on products controlled by software. Qua...
In addition to all the benefits, IoT is also bringing new kind of customer experience challenges - cars that unlock themselves, thermostats turning houses into saunas and baby video monitors broadcasting over the internet. This list can only increase because while IoT services should be intuitive and simple to use, the delivery ecosystem is a myriad of potential problems as IoT explodes complexity. So finding a performance issue is like finding the proverbial needle in the haystack.
The 19th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Digital Transformation, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportuni...
Large scale deployments present unique planning challenges, system commissioning hurdles between IT and OT and demand careful system hand-off orchestration. In his session at @ThingsExpo, Jeff Smith, Senior Director and a founding member of Incenergy, will discuss some of the key tactics to ensure delivery success based on his experience of the last two years deploying Industrial IoT systems across four continents.
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform. In his session at @ThingsExpo, Craig Sproule, CEO of Metavine, demonstrated how to move beyond today's coding paradigm and shared the must-have mindsets for removing complexity from the develo...
SYS-CON Events announced today that MangoApps will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. MangoApps provides modern company intranets and team collaboration software, allowing workers to stay connected and productive from anywhere in the world and from any device.
IoT is rapidly changing the way enterprises are using data to improve business decision-making. In order to derive business value, organizations must unlock insights from the data gathered and then act on these. In their session at @ThingsExpo, Eric Hoffman, Vice President at EastBanc Technologies, and Peter Shashkin, Head of Development Department at EastBanc Technologies, discussed how one organization leveraged IoT, cloud technology and data analysis to improve customer experiences and effi...
The IETF draft standard for M2M certificates is a security solution specifically designed for the demanding needs of IoT/M2M applications. In his session at @ThingsExpo, Brian Romansky, VP of Strategic Technology at TrustPoint Innovation, explained how M2M certificates can efficiently enable confidentiality, integrity, and authenticity on highly constrained devices.